Development of the new BRONJ cure targeted immunocompetent cells

Research Project

Project/Area Number	23592910
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Surgical dentistry
Research Institution	Hokkaido University
Principal Investigator	TEI Kanchu 北海道大学, 歯学研究科(研究院), 教授 (80180066)
Co-Investigator(Kenkyū-buntansha)	YOSHIMURA Yoshitaka 北海道大学, 大学院歯学研究科, 助教 (30230816) KIKUIRI Takashi 北海道大学, 大学院歯学研究科, 助教 (10322819)
Project Period (FY)	2011 – 2013
Project Status	Completed (Fiscal Year 2013)
Budget Amount *help	¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000) Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Keywords	歯学 / 顎骨壊死 / ビスフォスフォネート製剤 / ビスフォスフォネート
Research Abstract	Bisphosphonates-related osteonecrosis of the jaw (BRONJ) is a refractory disease that is osteonecrosis of the jaw in a patient who was receiving or had been exposed to bisphosphonate therapy. Here we conducted to consider whether it is possible to prevent BRONJ by anti-inflammatory drugs and elucidation of the pathogenesis of BRONJ. It was suggested that BRONJ occurred because of failure of the balance of immunity and the excessive inflammatory reaction by the analysis of the BRONJ model mouse. In addition, by the anti-inflammatory drugs, BRONJ was reduced. These results suggested that the anti-inflammatory drugs might prevent BRONJ or reduce a BRONJ symptom.